OR-RADISYS-CORPORATION
Radisys® Corporation , a global leader of open telecom solutions, today announced that Korean small cells player Qucell Networks is leveraging Radisys' Connect RAN gNodeB software to enable and deploy 5G small cell solutions for global markets. The integrated commercial-grade 5G small cell solution is being trialed in multiple operators’ networks across the globe.
Radisys’ 3GPP-compliant Connect RAN 5G software enables an elastic and agile 5G network tailored to meet the unique requirements of diverse 5G applications with minimized CAPEX, improved time-to-market, and shortened time-to-revenue. Qucell Networks’ 5G small cells meet varied requirements and enable multiple deployment scenarios in mmWave, Sub-6 GHz, Non-Standalone (NSA), Standalone (SA) and support advanced use cases in residential, enterprise, and outdoor scenarios.
News Highlights
- Radisys’ Connect RAN gNodeB software enables Qucell Networks’ 5G small cells to support high capacity, robust connectivity, low latency and secure 5G networks for advanced uses cases such as smart factories, healthcare, education, stadiums, enterprises, retail and other private 5G use cases.
- The ruggedized and feature-rich 5G small cell solution from Radisys and Qucell offers operators a commercial-grade, deployment-ready solution.
- Radisys’ Connect RAN 5G is the first-to-market protocol software compliant with 3GPP Release 16 and delivers enhancements in functionality, capacity, coverage, latency, mobility, reliability, and ease of deployment. It also supports the FAPI and nFAPI specifications from the Small Cell Forum (SCF), and it is compliant with O-RAN Alliance architecture. Connect RAN 5G software won the SCF Small Cell Award for Outstanding Contribution to Small Cell Open RAN Platforms.
- The software is available integrated on multiple industry-leading platforms to accelerate global 5G deployments.
“We are seeing growing demand for 5G small cells as global operators roll out their 5G networks and enterprises seek to deploy 5G private networks,” said Munish Chhabra, SVP and General Manager, Software and Services, Radisys. “We’ve teamed with Qucell to meet this demand with a pre-integrated, feature-rich solution for our customers.”
“We are excited to partner with Radisys on 5G small cells that deliver robust connectivity and high performance for a variety of indoor and outdoor use cases,” said Young-Soo Kwak, CEO, Qucell Networks. “Radisys is the leader in 5G software, and this integrated solution offers our joint customers an easy path to 5G deployment.”
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .
About Qucell Networks
Qucell Networks is a 5G and LTE small cells vendor and solutions provider. World-class mobile network operators have been deploying Qucell LTE solutions since 2012. What differentiates Qucell from competitors is a proven and commercially ready comprehensive suite of LTE and 5G small cells solutions. Qucell offers timely, effective turnkey products to solve real problems in commercial environments. Qucell partnerships with pioneers in small cells technology have resulted in proven cutting-edge products and professional services. For more information, visit QUCELL .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005157/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom